Opus Genetics Highlights Progress in Rare Retinal Gene Therapy at JPM26

Advancements in Rare Retinal Gene Therapy

According to reports from medicaldevice-network.com at the 2026 J.P. Morgan Healthcare Conference (JPM26), Opus Genetics is building momentum with its portfolio of rare retinal gene therapies. Inherited retinal diseases (IRDs) encompass more than 350 genetic mutations, highlighting a significant unmet clinical need for patients and families affected by these conditions.

Pipeline Highlights and Regulatory Progress

Source material from medicaldevice-network.com notes that Opus Genetics features a portfolio approach prioritizing indications with well-characterized biology, validated delivery methods, and measurable functional endpoints. Out of its seven gene therapy assets, two are currently in clinical trials, with more programs expected to enter the clinic.

Key updates include:
- OPGx-LCA5: This candidate has earned Orphan Drug, Rare Pediatric Disease, and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA. Following a Type B regulatory meeting, patient enrollment is underway for a planned adaptive Phase 3 trial, with dosing anticipated to begin in the second half of 2026.
- BIRD-1 Trial: The Phase 1/2 trial initiated dosing in late 2025. Early safety data supports continued patient enrollment, and initial efficacy data is expected in early 2026.
- Additional Assets: The company also maintains a partnered commercial asset, phentolamine ophthalmic solution 0.75%, alongside ongoing Phase III studies for dim-light visual disturbances.

What This Means for the IRD Community

For patients and families navigating inherited retinal diseases, ongoing clinical development and regulatory milestones represent critical steps toward potential therapeutic options. Opus Genetics reported a cash runway extending into 2027 alongside multiple anticipated data readouts through 2026, marking a period of active clinical evaluation in the rare ophthalmic space.

Looking Ahead

As clinical trials progress, the IRD community awaits further updates regarding the OPGx-LCA5 adaptive Phase 3 trial dosing and the upcoming efficacy data readouts from the BIRD-1 study.